
Opinion|Videos|November 27, 2024
Emerging Horizons in HER2-Directed NSCLC Treatments
Key Takeaways
- Recent trials, including SOHO-01, inetetamab/pyrotinib, and BEAMION Lung 01, show promising results for HER2-directed therapies in NSCLC.
- Advancements in targeting HER2 mutations suggest potential improvements in treatment efficacy and patient outcomes.
A review of recent clinical trial results for emerging HER2-directed therapies, including SOHO-01, inetetamab/pyrotinib, and BEAMION Lung-01, and their potential impact on the future treatment landscape for HER2-positive NSCLC.
Advertisement
Video content above is prompted by the following:
- Several HER2-directed therapies are currently in development. Could you discuss the recent clinical trial results for emerging agents, such as those from the SOHO-01, the inetetamab/pyrotinib combination study, and the BEAMION Lung 01 data and what implications might these findings have for the future landscape of HER2-directed therapies in NSCLC?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
4
Pricing and Insurance Networks in Outpatient Surgery Markets
5